Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
复制标题
DOI：
10.3390/cancers14071760
复制
发表时间：
2022-03-30
期刊：
影响因子：
5.2
通讯作者：
Ghobrial RM
中科院分区：
文献类型：
--
作者：
Abdelrahim M;Esmail A;Saharia A;Abudayyeh A;Abdel-Wahab N;Diab A;Murakami N;Kaseb AO;Chang JC;Gaber AO;Ghobrial RM
肝细胞癌是癌症相关死亡的第二大常见原因，占全球原发性肝癌的80%以上。在米兰标准中，只有一小部分HCC患者由于疾病晚期和肿瘤大阻碍/延迟器官分配而符合肝移植条件。最近，抗程序性细胞死亡蛋白1和程序性细胞死亡配体1 （PD-1和PD-L1）检查点抑制剂在癌症治疗中的应用发展迅速，这些疗法已被批准用于治疗HCC，然而，在接受icpi治疗的肝移植患者中，器官排斥反应的主要问题在移植前和移植后仍然是相同的。为了减轻这些担忧，需要更多的全球合作来探索icpi在器官移植前和移植后的安全性和有效性。对肝移植患者实施ICPI治疗的决定应根据护理目标和其他治疗方案的可得性和疗效逐案作出。肝细胞癌（HCC）是癌症相关死亡的第二大常见原因，占全球原发性肝癌的80%以上。小肿瘤的手术切除和射频消融是肝功能良好的HCC患者的治疗选择之一。根据米兰标准，只有一小部分HCC患者由于疾病晚期和肿瘤大阻碍/延迟器官分配而符合肝移植条件。最近，抗程序性细胞死亡蛋白1和程序性细胞死亡配体1 （PD-1和PD-L1）检查点抑制剂在癌症治疗中的应用发展迅速，这些疗法已被批准用于治疗HCC。免疫检查点抑制剂在移植前和移植后的HCC患者中产生了良好的临床结果，尽管一些报告显示某些受体可能面临排斥和移植物丢失。在这篇综述中，我们旨在说明和总结免疫检查点抑制剂治疗在HCC患者肝移植前和肝移植后的应用，并讨论可能决定肝移植结果的免疫检查点抑制剂调节因子的评估。
Hepatocellular carcinoma is the second most common cause of cancer-related deaths and accounts for over eighty percent of primary liver cancers worldwide. Regarding the Milan Criteria, only a small portion of HCC patients are eligible for liver transplantation due to advanced-stage disease and large tumor size preventing/delaying organ allocation. Recently, the use of anti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-1 and PD-L1) checkpoint inhibitors in the treatment of cancers have evolved rapidly and these therapies have been approved for the treatment of HCC, however, the main concerns about organ rejection in liver transplant patients who will be treated with ICPIs are still the same in both pre-and post-transplant setting. To alleviate those concerns, more global collaborations to explore the safety and efficacy of ICPIs in both the pre-and post-organ transplantation settings are required. The decision to administer ICPI treatment in liver transplant patients should be made on a case-by-case basis according to the goal of care and the availability and efficacy of other treatment options. Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related deaths and accounts for over eighty percent of primary liver cancers worldwide. Surgical resection and radiofrequency ablation in small tumors are included in the treatment options for HCC patients with good liver function profiles. According to the Milan Criteria, only a small portion of HCC patients are eligible for liver transplantation due to advanced-stage disease and large tumor size preventing/delaying organ allocation. Recently, the use of anti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-1 and PD-L1) checkpoint inhibitors in the treatment of cancers have evolved rapidly and these therapies have been approved for the treatment of HCC. Immune checkpoint inhibitors have resulted in good clinical outcomes in pre-and post-transplant HCC patients, although, some reports showed that certain recipients may face rejection and graft loss. In this review, we aim to illustrate and summarize the utilization of immune checkpoint inhibitor therapies in pre-and post-liver transplants for HCC patients and discuss the assessment of immune checkpoint inhibitor regulators that might determine liver transplant outcomes.
登录
查看更多内容
DOI：
10.7759/cureus.11150
发表时间：
2020-10-25
期刊：
Cureus
影响因子：
--
作者：
Al Jarroudi O;Ulusakarya A;Almohamad W;Afqir S;Morere JF
通讯作者：
Morere JF
影响因子：
8.4
作者：
Chau, Ian;Peck-Radosavljevic, Markus;Zhu, Andrew X.
通讯作者：
Zhu, Andrew X.
影响因子：
2.3
作者：
Gassmann D;Weiler S;Mertens JC;Reiner CS;Vrugt B;Nägeli M;Mangana J;Müllhaupt B;Jenni F;Misselwitz B
通讯作者：
Misselwitz B
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
影响因子：
11.5
作者：
Hodi, F. Stephen
通讯作者：
Hodi, F. Stephen